![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vc8ul8NVnCSpwKycP30lKMjER7IpkHDL6OKYJJmtbw8kCsdwdDD392LmFooZU-68aRhXlA0yDMjNW3paY5VY8-_DJrVNvqvKrLTX5Pi90=s0-d){kind=small}
Public release date: 11-Apr-2012[ | E-mail |
Share ] Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Lugano-CH/Aurora-US-CO, 11 April 2012 Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.
Three studies have been indicated as noteworthy:
Abstract 164O
First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 166O
Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 77O
Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer
Proffered Paper session, Friday, April 20, 14:30-16:00, Room C
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 11-Apr-2012[ | E-mail |
Share ] Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Lugano-CH/Aurora-US-CO, 11 April 2012 Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.
Three studies have been indicated as noteworthy:
Abstract 164O
First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 166O
Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms
Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B
Abstract 77O
Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer
Proffered Paper session, Friday, April 20, 14:30-16:00, Room C
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
us news law school rankings gael glen rice jr bars lindzi cox redskins bachelor finale
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.